Hospital Antibacterials A market beyond MRSA

The Hospital antibacterials market accounted for $9.9bn of the total $41bn anti-infectives market. Increasingly resistant and problematic pathogens make this an attractive target for premium priced products outside of the largely genericized Community market. However, high concentrations of patent expiries and similarly targeted product launches imply a highly competitive commercial landscape.

Scope of this report

* n-depth analysis of the hospital market sector across Japan, US, France, Italy, Germany Spain and the UK

* Product by product analysis of the key marketed and pipeline brands that will determine the market's evolution

* An assessment of key unmet needs and the opportunities they offer for new product development

* Case study analysis of the commercial implications of antibiotic drug development and commercialization

Research and analysis highlights

The total value of the hospital antibacterial market is $9.9bn, but generic incursion has caused this to slump over the 2003-2006 period. Within this market, a core group of products, accounting for $5.7 billion have managed to maintain a modest growth of 3%.

As sequential market leaders face patent expiry, competition within the generic industry will increase on oral formulations, leading select generic manufacturers to target the IV market with premium generic products.

High numbers of Gram-positive targeted products imply very distinct winners and losers. Astellas' Arbelic Cubicin and Zeven have strong commercial backing, but oritavancin, ceftaroline and subsequent entrants will find that generic incursion combined with the marketing might of strong entrants form a formidable barrier to the success.

Key reasons to read this report

* Balance the clinical and commercial aspects of key marketed and pipeline products to understand the future shape of the hospital antibacterials sector

* Understand the key supplemental clinical analysis that can make a critical difference to drug uptake post-approval

* Review the changes in class sales that signal the shift in prescribing practices resulting from prescribers' fear of resistance

Published: 24 August 2007

PDF Format
Table of Contents
Price: $15,200.00 / GBP7,600.00